Nanatinostat
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 29, 2018 (NCT03397706)
Timeline
Indications
Studied for
- Burkitt Lymphoma · Phase 2
- Carcinoma · Phase 1/Phase 2
- Epstein-Barr Virus Infections · Phase 2
- Hodgkin Disease · Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Extranodal NK-T-Cell · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoproliferative Disorders · Phase 2
- Nasopharyngeal Carcinoma · Phase 1/Phase 2
- Neoplasms · Phase 1
- Sarcoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NO)c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NCc2ccc3cc(F)ccc3n2)nc1- Mol. weight
- 394.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1801250 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06302140 | Phase 1 | Feb 28, 2024 | Viracta Therapeutics, Inc. |
| NCT05166577 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2021 | Viracta Therapeutics, Inc. |
| NCT05011058 | Phase 2 | Aug 31, 2021 | Viracta Therapeutics, Inc. |
| NCT03397706 | Phase 1/Phase 2 (Phase 2) | Mar 29, 2018 | Viracta Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viracta Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2018 |
1 organizations
Page 1 / 1